How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media patent could answer question of potential damages.
You may also be interested in...
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.
Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.